Similarly, inducing Bcl-2 overexpression in MCF-7 and MDA-MB-468 breast cancer cells by ABT-737, a Bcl-2 antagonist, can increase the efficacy of paclitaxel [94]. Here, BCL2 is linked to breast cancer.